CardioMech

Designing new therapeutic options for heart disease


The percutaneous approach

CardioMech is a Norwegian based company focused on providing a transcatheter alternative to cardiac surgery for the placement of artificial chords for the mitral valve.

We will prioritize treating high risk patients suffering from severe symptomatic degenerative mitral regurgitation due to prolapse or flail.

CardioMech estimates a prevalence of 440,000 patients in the USA and Europe. A $6 billion market opportunity.


Award Winning Technology

CardioMech's Nikolai Hiorth won the Young Investigator Award at the International Society for Medical Innovation and Technology Congress in Shanghai, China, 2014.


Partners




General inqueries

info@cardiomech.com
CardioMech AS
7030 Trondheim
Norway

CTO

nihi@cardiomech.com
Nikolai Hiorth


President and CEO

rick.nehm@cardiomech.com
Rick Nehm


Medical Director

jabe@cardiomech.com
Dr. Jacob Bergsland


CardioMech AS © 2018 · All rights reserved